

References:

1. **Abdallah, M.; Abdel-Naser, M. et al., (2001):**
Melanocytes findings in surgically treated vitiligo patients.
Egypt. J Derm and Androl; 21:71.
2. **Abdel Fattah, A.; Aboul Einenin, M. et al., (1982) :**
An approach to the treatment of vitiligo by Khellin.
Dermatologica, 165: 136.
3. **Abdel-Malak, Z.A.; Ross, R. et al., (1988):**
Hormonal effects of vitamin D³ on epidermal melanocytes. J
Cell Physiol; 136:273
4. **Abdel-Naser, M.B. et al. (1994):**
Further evidence for involvement of both cell mediated and
humoral immunity in generalized vitiligo. Pigment Cell Res.,
7:1-8.
5. **Abdel-Naser, M.B. (1999):**
Differential effects on melanocytes growth and melanization
of low vs. high calcium keratinocytes conditioned medium.
British Journal of dermatology; 140(1):p.50
6. **Abel, E.A.(1992):**
Acute & chronic side effects of PUVA therapy: Clinical and
histological changes. In: Photochemotherapy in Dermatology 1st
edit., Igakushoin publishers, Inc., New York. Tokyo, 207-223.
7. **Abel, E.A. (1995):**
Phototherapy. Dermatol Clin. Oct; 13 (4):841-9
8. **Acevedo, A.; Del Pozo, M. and Arroyo, A. (2000):**
Distribution of ICAM-3 bearing cells in normal human
tissues. Expression of a novel counter-receptor for LFA-1 in
epidermal Langerhans cells. Am J Pathol; 143:774.

9. **Adams, JC. and Watt, F. (1991):**
Expression of beta 1, beta 3, beta 4 & beta 5 integrins by human epidermal keratinocytes & non-differentiating keratinocytes. *J.cell.Biol*; 115:829-41.
10. **Agrawal, D.; Shajil, EM. et al., (2004):**
Study on the antioxidant status of vitiligo patients of different age groups in Baroda. *Pigment Cell Res*; 17(3):289-94.
11. **Al'Abadie, M.; Gawkrödger, D.; Senior, H. et al., (1992):**
Neuroultrastructural & neuropeptide studies in vitiligo. *Clin. Exp. Dermatol.* , 15:284.
12. **Al'Abadie, M.S.; Warren, M.A. et al., (1995) :**
Morphologic observations on the dermal nerves in vitiligo: An ultrastructural study. *Int. J. Dermatol.* , 34: 837.
13. **Al-Aboosi, M.M. and Ajam ,Z.A., (1995):**
Oral photochemotherapy in vitiligo: Follow-up, patient compliance. *Int J Dermatol* 34:206-208.
14. **Al-Badrie, A.; Foukis,A.; Todd, P. et al., (1995) :**
Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. *J. Pathol.*, 169:203-206.
15. **Allan, E. et al., (1995):**
Topically applied diacylglycerols increase pigmentation in guinea pig skin. *J.Invest.Dermatol.*, 105:687.
16. **Amagi, M. (1995):**
Adhesion molecules. In: *Keratinocyte with keratinocyte interactions; cadherins and pemphigus.* *J.Invest Dermatol*,104:146.
17. **Ameen, M.; Exarchou, V. et al., (2001):**
Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. *Br J Dermatol*; 145:476

18. **Anderson, R.R. and Parrish, J.A. (1982):**
Optical properties of human skin. In: Regan, JD.; Parish JA.; eds. The Science of Photomedicine. New York : Plenum Press, p.147. Quoted from Hawk,(1998).
19. **Anderson, E.; Rosdahl, L. et al., (1999):**
Ultraviolet irradiation depletes cellular retinol and alters the metabolism of retinoic acid in cultures human keratinocytes and melanocytes. *Melanoma Res*; (4):339
20. **Anthony, F.A. et al., (1997):**
Psoralen-fatty acid adducts activate melanocyte protein kinase C: A proposed mechanism for melanogenesis induced by 8-methoxypsoralen and ultraviolet A by light. *Photodermatol. Photoimmunol. Photomed.*, 13:9.
21. **Arnaout, A. (1990):**
Structure & function of leukocyte adhesion molecules CD11/CD18. *Blood*; 75:1037.
22. **Averbeck, D. et al., (1984):**
Mutagenic effects of psoralens in yeast and V79 Chinese hamster cells. *Monogr. Natl. Cancer Inst.*, 66:127. Quoted from Honigsmann H.; Fitzpatrick TB.; et.al.; (1992).
23. **Badri, A.M.; Todd, P.M.; Garioch, J.J. et al., (1993) :**
An immunohistological study of cutaneous lymphocytes in vitiligo. *Pathol.* , 170 (2): 149.
24. **Bahadoran, P. et al., (2003):**
Hypomelanoses, immunity, central nervous system: No more "and", not the end. *Am.J.Med.Genet*; 116A:334.
25. **Baltas, E.; Kemeny, L. et al., (1997):**
308 nm UVB excimer laser for psoriasis. *Lancet*; 350:1522 (letter).
26. **Baltas, E.; Nagy, P. et al., (2001):**
Repigmentation of localized vitiligo with the xenon chloride laser. *Br J Dermatol*; 144:1266

27. **Barona, M.I.; Arrunategui, A.; Falabella, R. et al., (1995) :**
An epidemiologic case-control study in a population with vitiligo. *J Am Acad Dermatol* 33:621-5.
28. **Basis, O. et al., (1980):**
Absence of cataract ten years after treatment with 8 methoxypsoralen. *Acta. Derm. Venereol. (Stockh)*, 60:79.
29. **Bergfeld, W.F. (1977) :**
Histopathologic changes in skin after photochemotherapy. *Cutis*, 20:504. Quoted from (Goldstein, 1992b)
30. **Bleehan, S.S.; Ebling, F.J.G. and Champion, R.H. (1999):**
Disorders of skin color. In: Rook, Wilkinson, Ebling Textbook of Dermatology. RH Champion, JI Burton and FJG Ebling (eds). Fifth edition, Blackwell Scientific Publications, London, Edinburg, Boston: 1561
31. **Bleijs, D.A. et al., (2000):**
Co-stimulation of T-cells results in distinct IL-10 and TNF- α cytokine profiles dependent on binding of ICAM-1, ICAM-2 and ICAM-3. *Eur J Immunol*; 29:2248.
32. **Bochner, B.S.; Sterbinsky, S.A. and Bickel, C.A. (1994):**
Difference between human eosinophils and neutrophils in the function and expression of sialic acid containing counterligands for E-selectin. *J Immunol*; 152:774
33. **Boersma, B.R.; Westerhof, W. and Bos, J.D. (1995):**
Repigmentation in vitiligo vulgaris by autologous minigrafting *J Am Acad Dermatol*; 33:990
34. **Boiognia, J.L.; Lapia, K. et al., (2001):**
Depigmentation therapy. *Dermatol ther*; 14:29
35. **Boissy, R.E.; Liu, Y.; Medrano, E. et al.,(1991):**
Structural abnormalities of rough endoplasmic reticulum & melanosome compartmentalization in long-term culture of melanocytes from vitiligo patients. *J. Invest. Dermatol*; 97:395-404.

36. **Boissy, R.E. and Norduland, J.J. (1995):**
Biology of melanocytes. In Cutaneous Medicine and Surgery (Arndt KA. et al., eds) pp. 1203 – 1209 WB. Saunders Co. Philadelphia PA. USA.
37. **Bologna, J. and Pawelek, J.M. (1988):**
The biology of hypopigmentation. J.A.M. Acad. Dermatol., 19:217.
38. **Bor, S. (1973):**
Clofazimine (lamperene) in the treatment of vitiligo. S Afr Med J; 47:1451. Quoted from (Golstein et al., 1992b) ←
39. **Braun-Falco, O.; Plewig, G. et al., (1991):**
In: Dermatology; 4th edition, Springer Verlag-Berlin. Chapter 26: Disorder of melanin pigmentation; p.686.
40. **Burkhart, C.G. and Burkhart, C.N. (1999):**
Phenylalanine with UVA for the treatment of vitiligo needs more testing for possible side effects. J Am Acad Dermatol; 40:6.
41. **Burrows, N.P. and Norris, P.G. (1994):**
Treatment of PUVA induced skin pain with capsaicin. Br. J. Dermatol., 131:584-5.
42. **Cagnoni, M. et al., (1993):**
Cell adhesion molecule in inflammatory & neoplastic skin disease. J. Eur. Acad. Dermatol.; 2:94.
43. **Caixia, T.; Hongwen, F. and Xiran, L. (1999):**
Levels of sIL-2R in the sera and skin tissue fluids of patients with vitiligo. J. Invest. Dermatol., 108:527-529.
44. **Campbell, M.J. and Machin, D. (1993):**
Medical Statistics. A common sense approach. 2nd ed. John Wiley and Sons. New York, Chichester, Brisbane, Toronto and Singapore.
45. **Cao, C.M. (1986) :**
Melagenine : A Cuban product. A new and effective drug for the treatment of vitiligo. Series of National Reports. Republic of Cuba Havana. Quoted from Grimes.[1993].

46. **Carlo, B.M and Harlan, J.M. (1998):**
Leukocyte-endothelial adhesion molecules. *Blood*, 84:2068
47. **Carlos, T.M.; Schwart, B.R. et al., (1990):**
Vascular adhesion molecule-1 (VCAM-1) mediates lymphocytes adherence to cytokine activated cultured human endothelial cells. *Blood*; 76:965.
48. **Carmela, V.; Richard, V. and Warren, R. (2003):**
Cryotherapy. *American Academy of Dermatology*. Jan 6.
<http://www.emedicine.com/derm/topic553.htm>.
49. **Carter, R. (1992) :**
Williams & Wilkins. A dictionary of dermatologic term.
Baltimore (MD). Quoted from (Kovasc, 1998)
50. **Chen, A.J.; Engel, P. and Tedder, T.F. (1995):**
Structural requirements regulate endoproteolytic release of the L-selectin (CD62L) adhesion receptor from the cell surface of leukocytes. *J.Exp.Med*; 182:519-30.
51. **Chen, Y.F.; Chang, J.S. et al., (2000):**
Transplant of cultured autologous pure melanocytes after laser-abrasion for the treatment of segmental vitiligo. *J Dermatol*; 27(7):434
52. **Claudy, A. and Rouchouse, B. (1994) :**
Langerhans cells and vitiligo : Quantitative study of T6 and HLA-DR antigen-expressing cells. *Acta. Derm. Venereol. (Stockh)*, 64:334-336
53. **Cole, R.S. (1971):**
Psoralen monoadducts and interstrand cross-links in DNA *Biochem. Biophys. Acta.*, 254:30. Quoted from Honigsmann H.; Fitzpatrick TB.; et.al., (1992).
54. **Cormane, R.H.; Siddiqui, A.H. et al., (1985):**
Phenylalanine and UVA light for the treatment of vitiligo. *Arch. Dermatol. Res.*, 277:126.

55. **Cormane, R.H.; Siddiqui, A.H. et al., (1986) :**
Treatment of vitiligo with L phenylalanine and light. *Br. J. Dermatol.*, 115:587.
56. **Cowan, C.L.; Halder, R.M. et al., (1986):**
Ocular disturbance in vitiligo. *J.Am.Acad.Dermatol.*, 19 :217.
57. **Cox, N.H.; Jones, S.K. et al., (1987):**
Cutaneous and ocular effects of oral photochemotherapy: Results of an 8-year follow-up study. *Br.J.Dermatol*, 116:145.
58. **Cristofolini, M. et al., (1990):**
6 methylanglicins: New monofunctional photochemotherapeutic agents for psoriasis *Br.J.Dermatol.* , 122:513. Quoted from Honigsmann H.; et al., (1992).
59. **Cui, J. (2004):**
Monograph on the basic and clinical science. 1st ed. New York: Blackwell Science; p.163-7.
60. **Cui, J.; Arita, Y. and Bystryn, J.C. (1995):**
Characterization of vitiligo antigens. *Pigment Cell Res.* 8; 53-59
61. **Daniel, W. (1987):**
Biostatistics, a foundation for analysis in the health science. 4th ed. John Wiley & Sons. New York, Chichester, Brisbane, Toronto and Singapore.
62. **Danno, K.; Toda, K. and Horio, T. (1986):**
The effect of 8-methoxypsoralen plus long-wave ultraviolet (PUVA) radiation on mast cells: PUVA suppresses degranulation of mouse skin mast cells induced by compound 48/80 or Concanavalin A. *J.Invest.Dermatol.*, 85:110.
63. **Deeths, M.J. and Mescher, M.F. (2000):**
ICAM-1 and B7-1 provide similar but distinct co-stimulation for CD8⁺ T-cells, while CD4⁺ T-cells are poorly co-stimulated by ICAM-1. *Eur J Immunol*; 29:45.
64. **De Fougères, A.; Stacker, S. et al., (1997):**
Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1. *J Exp Med*; 174:253

65. **De Fougérolles, A.; Klickstein, I. and Springer, T. (1999):**
Intercellular adhesion molecule-3, a third adhesion counter-receptor for LFA-1 on resting lymphocytes. *J.Exp.Med* 175:185.
66. **De Fougérolles, A.R.; Klickstein, L.B. et al., (2000):**
Cloning and expression of intercellular adhesion molecule 3 reveals strong homology to other immunoglobulin family counter-receptors for lymphocytes function-associated antigen 1. *J.Exp.Med*, 117:1187.
67. **Delisser, H.M.; Newman, P.J. et al., (1993):**
Platelet endothelial cell adhesion molecule (CD31). *Curr.Top. Micro.Immunol.*; 184:37.
68. **Diamond, M.S.; Staunton, D.E. et al., (1991):**
Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. *Cell*; 65:961
69. **Duff, J.L.; Quinlan, K.L. et al.,(1997):**
Prevanadate mimics IFN- γ mediated induction of ICAM-1 expression via activation of STAT proteins. *J Invest Dermatol*, 108:295.
70. **Dunston, G.M. and Halder, R.M. (1990):**
Vitiligo is associated with HLA-DR4 in black patients. A preliminary report. *Arch. Dermatol.*, 126(1):56.
71. **Dupre, A. et al., (1980):**
Lichen planus avec photosensibilisation apres pyritinol et PUVA-therapie. *Ann. Dermatol. Venereol.* 107:557-9.
72. **Dustin, M.L.; Rothlein, R. et al., (1996):**
Induction of IL-1 and INF- γ , tissue distribution, biochemistry ,and function of a natural adherence molecule (ICAM-1).*J.Immunol.*;137:245.
73. **Elliott, J. (1959):**
Clinical experiences with methoxasalen in the treatment of vitiligo. *J.Invest.Dermatol*, 32:311. Quoted from (Kovasc, 1998)

74. **El-Mofty, A.M. (1948):**
A preliminary clinical response on the treatment of leukoderma with Ammi Majus Linn. J.Royal Egypt. Med. Assoc., 31:651. Quoted from (Kovasc, 1998)
75. **El-Mofty, A.M. (1952a) :**
Observations on the use of Ammi Majus Linn in vitiligo. Br.J.Dermatol, 64:431. Quoted from (Kovasc, 1998)
76. **El-Mofty, A.M. (1952b):**
Further study on treatment of leukoderma with Ammi Majus Linn . J.Egypt.Med.Assoc, 35:1. Quoted from (Kovasc, 1998)
77. **El Mofty, A.M.; El Sawahly, H. et al., (1994):**
Clinical study of a new preparation of 8-methoxypsoralen in photochemotherapy. Int.J.Dermatol, 33:588.
78. **El Mofty, M.E.; Zaher, H. et al., (2001):**
PUVA and PUVB in vitiligo: Are they equally effective? Photodermatol Photoimmunol Photomed; 17:159
79. **Epestein, J.H. and Fukuyame, K. (1975):**
Effects of 8-methoxypsoralen-induced phototoxic effects on mammalian epidermal macromolecule synthesis in vivo. Photochem. Photobiol, 21:325 (abstract). Quoted from (Honigsmann et al., 1992)
80. **Ermis, O.; Alpsoy, E. et al., (2001):**
Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo controlled double-blind study. Br J Dermatol; 145:472
81. **Eyanson, S.; Geist, M.C. et al., (1979):**
Systemic lupus erythematosus. Association with psoralen-ultraviolet. A treatment of psoriasis. Ach. Dermatol., 115:54. Quoted from (Goldstein, 1992b)
82. **Fahmy, I.R.; Abu-Shady, H. et al., (1947):**
A crystalline principle from Ammi Majus Linn.Nature, 160:468.
Quoted

-
83. **Falabella, R. (2000):**
Surgical therapies for vitiligo, in vitiligo, edited by SK Hann, JJ Nordlund. London, Blackwell Science. P 193
84. **Falabella, R.; Escobar, C. and Borrero, I. (1992):**
Treatment of refractory and stable vitiligo by transplantation of in vitro cultured epidermal autografts bearing melanocytes. J. Am. Acad. Dermatol; 26:230-6.
85. **Farah, F.; Kurban, A. et al., (1967):**
The treatment of vitiligo with psoralen and triamcinolone by mouth. Br.J.Dermatol; 79:89. Quoted from (Kovasc, 1998)
86. **Farber, E.M. et al., (1986):**
Stress, symmetry and psoriasis: Role of neuropeptides. J. Am. Acad. Dermatol;
87. **Felming, F. (1990):**
Cellular functions of adhesion molecules. J. Pathol. ; 161 (3):189.
88. **Fitzpatrick, T.B. (1964):**
Hypomelanosis. South Med. J., 57: 995 - 1005. Quoted from (Kovasc, 1998).
89. **Fitzpatrick, T.B. and Ortoone, J.P. (2003):**
Normal skin color and general considerations of pigmentary disorders. Text book of Fitzpatrick's Dermatology In General Medicine 6th edition. The McGraw-Hill Companies, Inc. p. 819.
90. **Fritsch, P.O. et al., (1979):**
PUVA suppresses the proliferative stimulus produced by stripping on hairless mice. J. Invest. Dermatol., 73:188. Quoted from (Honigsmann et al., 1992)
91. **Gauthier, Y. and Surleve-Bazeille, J. (1992):**
Autologous grafting with noncultured melanocytes: a simplified method for treatment of depigmented lesions. J.Am.Acad. Dermatol; 26:191-4.
-

92. **Gearing, A.J. and Newman, W. (1994):**
Circulating adhesion molecules in disease. *Immunol Today*; 14:506-12.
93. **George, F. Murphy (1995):**
Dermatopathology. A practical guide to common disorders; ch.17 cutaneous pigmentary disorders p.318-319. W.B. Saunders Company. A division of Harcourt brace & Company. Philadelphia London Toronto Monterial Sydney Tokyo.
94. **Gibbs, N.K. et al., (1986):**
PUVA treatment strategies and cancer risk. *Lancet*, 1:150.
95. **Giffin, A.C.; Hakim, R.E. et al., (1985):**
The wave length effect upon erythematous and carcinogenic response in psoralen treated mice. *J. Invest. Dermatol*, 31:289.
96. **Gilhar, A. et al., (1995):**
In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. *J. Invest. Dermatol*. 105; 683-686.
97. **Gilmour, J.W.; Vestey, J.P. et al., (1993):**
Effect of phototherapy and urocranic acid isomers on natural killer cell function. *J. Invest. Dermatol*, 101(2):169.
- 98. **Goldgeier, M.; Klein, L.; Klein-Angerer, S. et al., (1984):**
The distribution of melanocytes in the leptomeninges of the human brain. *J Invest Dermatol* 82:235.
99. **Goldstein, E.; Haberman, H.F. et al., (1992a):**
Non-psoralen treatment of vitiligo. Part I. Cosmetics, systemic coloring agents, and corticosteroids. *Int J Dermatol* 31:229-36.
100. **Goldstein, E.; Haberman, H.F. et al., (1992b):**
Non-psoralen treatment of vitiligo. Part II. Cosmetics, systemic coloring agents, and corticosteroids. *Int J Dermatol* 31:314
101. **Goolamali, S.K. (1973):**
Topical levodopa in vitiligo. *Lancet*; 1:675. Quoted from (Goldstein et al., 1992b)

102. Grimes, P.E. et al., (1982):
Determination of optimal topical photochemotherapy for vitiligo. J.Am.Acad.Dermatol., 7:771.
103. Grimes, P.E. et al., (1983):
Vitiligo: racial variations in the response to topical photochemotherapy. J. Invest. Dermatol., 80:367.
104. Grimes, P.E. (1993):
Vitiligo. An overview of therapeutic approaches. Dermatologic Clinics, 11:325.
105. Grimes, P.E. (1996):
In Principles and Practice of Dermatology, eds.; W. Mitchell Sams and P.J. Lench. 2nd edition Churchill Livingstone Publishers chapter 22: Diseases of Hypopigmentation, p.843.
106. Grimes, P.E.; Ghoneum, M.; Stockton, T. et al., (1986):
T-cell profiles in vitiligo. J. Am. Acad. Dermatol., 14:196.
107. Grimes, P.E. and Kelly, A.P. (1986):
Management of vitiligo in children. Paed.Dermatol., 3:498.
108. Grimes, P.E.; Soriano, T. et al., (2002):
Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol; 47 (5):789
109. Gschnait, F.; Wolff, K. et al., (1980):
Long-term photochemotherapy: histopathological and immunofluorescence observations in 243 patients. Br. J. Dermatol., 103:11.
110. Guilhou, J.J. (2001):
Calcipotriol. Ann Dermatol Venereol; 128:229
111. Gupta, A.K.; Haberman, H.F. et al., (1985):
Canthaxanthin. Int J Dermatol; 24:528
112. Gupta, A.K.; Ellis, C.N. et al., (1990):
Oral cyclosporin in the treatment of inflammatory and non-inflammatory dermatoses. Arch Dermatol; 126:339

113. Gupta, S.; Shroff, S. and Gupta S. (1999):
Modified technique of suction blistering for epidermal
grafting in vitiligo. *Int. J. Dermatol*; 38:306-309. } *الفرد*
114. Gupta, S. and Kuman, B. (2000):
Suction blister induction time: 15 minutes or 150 minutes.
Dermatol Surg; 26(8):754-6.
115. Gupta, S. and Kumar, B. (2002):
Epidermal grafting for vitiligo in adolescents. *Ped Dermatol*;
46 (6):727
116. Gwen V. Childs. (2001):
Adhesion molecule:
<http://cellbio.utmb.edu/Cellbio/adhesion-moleculeshtm>.
E-mail gychilds @utmb.edu(409) 772-1942.
117. Halcin, C. et al., 1997):
Vitiligo following the resolution of psoriatic plaques during
PUVA therapy. *Int. J. Dermatol. Jul.*, 36 (7):534-6. Quoted from
(Goldstein, 1992b)
118. Halder, RM. et al., (1987):
Childhood vitiligo. *J. Am. Acad. Dermatol.* 16:948. Quoted from
Andrews Diseases of the skin, 9th edition. Copyright 2000 by
W.B. Saunders Company. Philadelphia, Pennsylvania 19106. }
119. Halder, R.M. ; Pham, H. et al., (1989):
Micropigmentation for the treatment of vitiligo. *J. Dermatol.*
Surg. Oncol. , 15 :1092. Quoted from Grimes. (1993)
120. Halder, R. and Young, M., (2000):
New emerging therapies for vitiligo. *Dermatologic Clinics*; 1:79
121. Hann, S.K; Bong, H.W. et al., (1995):
Treatment of stable vitiligo with autologous epidermal grafting
and PUVA. *J. Am. Acad. Dermatol*; 32:943-8.
122. Hann, S.K; Chung, H.S; Dark, Y.k. et al., (1997):
Epidemiologic case control study in patients with vitiligo [letter]
J Am Acad Dermatol 36 :282-3.

123. **Hann, S.K. and Chun, W.H. (1997):**
Correspondence. *J Am Acad Dermatol*; 36:803.
124. **Hann, S.K. and Nordlund, J.J. (2000):**
Definition of vitiligo, in *Vitiligo*, edited by SK Hann, JJ Nordlund. London, Blackwell Science, p 3.
125. **Harning, R.; Cui, J. and Bystry, J.C. (1991):**
Relation between the incidence & level of pigment cell antibodies & disease activity in vitiligo. *J. Invest. Dermatol.* 97; 1078-1080.
126. **Hearing, V.J. (2000):**
The melanosome: The perfect model for cellular responses to the environment. *Pigment Cell Res*; 13:23-34.
127. **Hedley, S.J. et al., (1998):**
Vitiligo melanocyte in long term culture show normal constitutive & cytokine-induced expression of ICAM-1 & MHC class I & II molecules. *Br. J. Dermatol.* 139; 965-973.
128. **Hedstrand, H. et al., (2001):**
The transcription factors SOX 9 and SOX 10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type 1. *J. Biol. Chem* (in press).
129. **Helen, E. Kemp; Elizabeth, A. and Anthony, P. Weetman. (2001):**
Immunological pathomechanisms in vitiligo.
*Exp.Rev.Mol.Med.*23July,
<http://www.ermm.cbcu.can.ac.uk/01003362h.htm>.
130. **Helland, S. and Bang, G. (1980):**
New spilus-like hyperpigmentation in psoriatic lesions during PUVA therapy. *Acta. Derm. Venereol. (Stockh)*,60:81.
131. **Henseler, T.; Honigsmann, H. et al., (1981):**
The European PUVA study (EPS): Oral 8-methoxypsoralen photochemotherapy of psoriasis. A cooperative study among 18 European centers. *Lancet*,1:853.

-
132. Henseler, T. et al., (1987):
Skin tumors in the European PUVA study. Eight years follow-up of 1,643 patients treated with PUVA for psoriasis. *J. Am. Acad. Dermatol.*;16:108.
133. Hertle, M.D.; Kubler, M.D. et al., (1992):
Aberrant integrin expression during epidermal wound healing & in psoriatic epidermis. *J. Clin. Invest.*; 89:1892-901.
134. Hiroaki, Y.; Yoshiki, T. et al., (1997):
Vitiligo with raised inflammatory borders: Involvement of T cell immunity & keratinocytes expressing MHC class II & ICAM-1 molecules. *European J. of Dermatology*; (7):1, 19-22.
135. Honig, B. et al., (1994):
Photochemotherapy beyond psoriasis. *J. Am. Dermatol.*, 31:775.
136. Honigsmann, H. et al., (1987):
5-Methoxypsoralen (bergapten) in photochemotherapy of psoriasis. *Br. J. Dermatol.*;101:369-378.
137. Honigsmann, H.; Wolff, K. et al., (1982):
Keratosis and non-melanoma skin tumor in long term photochemotherapy (PUVA). *J. Am. Acad. Dermatol.*; 3:406. 1 الحزب
138. Honigsmann, H.; Fitzpatrick, T.B. et al., (1992):
Oral photochemotherapy with psoralen and UVA (PUVA): Principles and practice. In: Fitzpatrick TB., et al.(eds). *Dermatology in General Medicine*. McGraw Hill, New York pp. 1728-54.
139. Horio, T. and Okamoto, H. (1982):
The mechanism of inhibitory effects of 8-methoxypsoralen and long wave ultraviolet A light on experimental contact sensitization. *J. Invest. Dermatol.*; 78:402.
140. Howantiz, N.; Nordlund, J.; Lerner, A. et al., (1981):
Antibodies to melanocytes. *Arch. Dermatol.*; 117:705.
-

-
141. **Howitz, J.; Brodthagen, H.; Schwartz M. et al., (1977):**
Prevalence of vitiligo. Arch Dermatol. 113:47-52. Quoted from
Rook/Wilkinson/Ebling. Textbook of dermatology 6th edition.
Copyright 1998; edited by Champion et al.
142. **Hwang, A.J.; Manning, J.E.; Badnda, K.T.M. et al., (1999):**
Endothelial cell cytosolic free calcium regulates neutrophils
migration across monolayers of endothelial cells. J.cell
Biol;120:1371.
143. **Hwang, J.H.; Ahn, J.S. et al., (2000):**
The changes of serum sICAM-1 after systemic steroid
treatment in vitiligo. J Dermatol Sci; 22(1):11-6
144. **Hynes, R.O. (1992):**
Integrins versatility, modulation.& signaling in cell adhesion.
Cell; 69:11-25.
145. **Ibbotson, S.H. and Farr, P.M. (1999):**
The time-course of psoralen ultraviolet A (PUVA) erythema.
J Invest Dermatol 113:346.
146. **Imokawa G. et al., (1996):**
Granulocyte/macrophage colony-stimulating factor is an
intrinsic keratinocyte-derived growth factor for human
melanocytes in UVA- induced melanoses. Biochem J 313, 625-
631.
147. **Irwan, M.; Arthur, Z. et al., (2003):**
Hypomelanoses and hypermelanoses Text book of
Fitzpatrick's Dermatology In General Medicine 6th edition.
The McGraw-Hill Companies, Inc. pp836-881.
148. **Ivan, R. et al., (1993):**
Intercellular adhesion molecules. Text book of immunology 3rd
edition. Mosby. St. Louis Baltimore Boston Chicago London
Philadelphia Sydney Toronoto pp 13-30.
149. **James, J. Norduland. (2003):**
National vitiligo foundation 611 South Fluish Ave. Tyler TX
75701. E mail:Vitiligo@ballistic.Com
-

150. **Jennifer, C.; Grahn, B.S. et al., (2003):**
Melanocytes do not migrate directionally in physiological DC electric fields. *Wound Rep Reg*; 11:64-70
151. **Jones, C. and Bleehan, S.S. (1977):**
Acne induced by PUVA treatment. *Br. Med. J.*, 2:866. } *Quoted from*
152. **Jimbow, K. (1998):**
Vitiligo, therapeutic advances. *Dermatologic Clinics*, 16(2):399.
153. **Jimbow, K.; Kaidbey, K.H. et al., (1974):**
Melanin pigmentation stimulated by UVB and UVA and psoralen. *J. Invest. Dermatol.*, 62:548. Quoted from (Goldstein, 1992a)
154. **Johnson, R.; Staiano-Coico, L. et al., (1996):**
PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in normal and malignant T-lymphocytes. *Photochem Photobiol*; 63:566-71
155. **Johnston, G.I.; Bliss, A. et al., (2001):**
Structure of the human gene encoding granule membrane protein 140, a member of the selectin family of adhesion receptors for leukocytes. *J. Biol. Chem.*; 265:21381.
156. **Jones, C. and Bleehan, S.S. (1977):**
Acne induced by PUVA treatment. *Br. Med. J.* 2:866. Quoted from (Goldstein, 1992b)
157. **Juhlin, L. and Olsson, M.J. (1997):**
Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. *Acta Derm Venereol*; 77:460
158. **Jung, T.M. and Dailey, M.O. (2000):**
Rapid modulation of homing receptors with activators of protein kinase C. *J. Immunol.*, 144:3130.
159. **Jutila, M.A. et al., (2000):**
L-selectin. *J. Immunol* 143. 3318.

160. **Kaidbey, K.H. (1985):**
An action spectrum for 8-MOP sensitized inhibition of DNA synthesis in vivo. *J. Invest. Dermatol.*,85:98.
161. **Kato, M.; Hattoi, T. et al., (1996):**
Amount of pollen has an effect on the systemic & local levels of sICAM-1 in patients with allergic rhinitis. *Allergy.*; 51:128-32.
162. **Katz, A.M.; Rosenthal, D. et al., (1991):**
Cell adhesion molecules. *Int.J.Dermatol.*; 30:153.
163. **Kavanagh, G.; Crosby, J. et al., (1995):**
→ Urocanic acid isomers in human skin : analysis of site variation
. *Br.J.Dermatol.*,133(5)728.
- 164. **Kawakami, Y.; Robbins, P.F. and Roseberg, S.A. (1996):**
Human melanoma antigens recognized by T lymphocytes. *Keio J Med* 45 : 100-8.
165. **Keahey, T.M.; Lauker, R.M. et al., (1984):**
Studies on the mechanism of clinical tolerance in solar urticaria. *Br. J. Dermatol.*, 110:327.
166. **Kellner, I.; et al., (1991):**
Overexpression of extracellular matrix receptors (VLA-3,5 and6) on psoriatic keratinocytes.*Br. J. Dermatol.*;125:211.
167. **Kemp, E.H. et al. (1998):**
Autoantibodies to tyrosinase-related protein detected in the sera of vitiligo patients using a quantitative radioabing assay. *Br. J. Dermatol.* 139;798-805.
168. **Kenny, J.A. (1988):**
Vitiligo. *Dermatol. Clin.*,6:425.
169. **Kent, G. and Al'Abadie, M. (1996):**
Psychological effects of vitiligo. A critical incident analysis. *J. Am, Acad Dermatol.*,35:895.
170. **Kim, Y.J.; Chung, B.S. et al., (2001):**
Depigmentation therapy with Q-switched ruby laser after tanning in vitiligo universalis. *Dermatol Surg*; 27:969

171. Kirby, B. and Rogers, S. (1997):
Treatment of PUVA itch with capsaicin. Br. J. Dermatol.,137(1):152.
172. Kirnbauer, R.; Charvat, B. et al., (1992):
Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: evidence for a regulatory role of IL-6, IL-7, TNF- β and UVB light. J Invest Dermatol Mar; 98(3):320-6.
173. Kishimoto, T.K. and Anderson, D.C. (1992):
The role of integrins in inflammation In. Gallin JI., Inflammation: Basis Principles & Clinical correlates. New York Rawen Press, pp.200.
174. Klaus, D. Elgert. (2001):
Immunology. Understanding the immune system. Chapter 19, the T-cell receptor complex. A Johny Wihy and sons. Inc. Publication New York. Chichester. Brisbane Toronto Singapore p.192.
175. Klim, C.Y.; Yoon, T.J. and Kim, T.H. (2001):
Epidermal grafting after chemical epilation in the treatment of vitiligo. Dermatol Surg; 27(10):855-6
176. Koga, M., (1988) :
Vitiligo; A new classification and therapy. Br. J. Dermatol.; 97: 255. Quoted from (Kovasc, 1998)
177. Koga, M. and Tango, T. (1988):
Clinical features and course of type A and type B vitiligo. Br. J. Dermatol; 118:223.
178. Koga, M. (1998):
Epidermal grafting using the tops of suction blisters in the treatment of vitiligo. Arch Dermatol; 124:1656-8.

- 179. Koivukangas, V. and Oikarinen, A. (1998):**
Effects of PUVA and UVB treatments on restoration of epidermal barrier function and vascular response after suction blister injury in human skin in vivo. *Photodermatol Photoimmunol Photomed*; 14 (3-4):119-24.
- 180. Koster, W. and Wiskemann, A. (1990):**
Phototherapy with UVB in vitiligo. *Z Hautkr*; 65(1):1022. (abst.).
- 181. Kovasc, O. (1998):**
Vitiligo: *J.Am. Acad*; 38:647
- 182. Kowichi, J. (1998) :**
Vitiligo, therapeutic advances. *Dermatologic clinics*; 16:399.
- **183. Kragballe, K. (1997):**
The future of vitamin D in dermatology. *J Am Acad Dermatol*; 37(suppl):72
- 184. Kripke, M.L.; Morison, W.L. et al., (1983):**
Systemic suppression of contact hypersensitivity in mice by psoralen plus UVA radiation (PUVA). *J. Invest. Dermatol*; 81:87.
- 185. Krueger, G. James. (2002):**
The immunologic basis for the treatment of psoriasis with new biologic agents. *J Am Acad Dermatol*; 46:1-23
- 186. Kumakiri, M. and Hashimoto, K. (1978):**
Cutaneous nerve stimulation by psoralen-Ultraviolet A therapy: An ultrastructural study: *J.Invest.Dermatol*; 70:163.
→ Quoted from (Honigsmann et al., 1992)
- 187. Kumari, J. (1984):**
Vitiligo treated with topical clobetasol propionate. *Arch. Dermatol*; 120:631.
- 188. Lacour, J.P. and Ortonne, J.P. (1995):**
Genetics of vitiligo. *Ann. Dermatol. Venereol*; 122 (4):167.

189. **Lamoreux, M.; Boissy, R.; Womack, J. et al., (1992):**
The vit gene maps to the microphthalmia locus of the laboratory mouse. *J. Hered*; 83:435-9. } Quoted
190. **Langer, A.; Wolska, H. et al., (1976):**
Photochemotherapy (PUVA) and psoriasis: comparison of 8-MOP and 8-MOP / 5-MOP. *Int. J. Dermatol*; 15:688. Quoted from (Kovasc, 1998)
191. **Lasky, L. (1995):**
Adhesion molecules. *Annu. Rev. Biochem*; 64:113.
192. **Lasky, L. (1999):**
P-selectin. *Current Biol*; 3:680.
193. **Lassus, A. et al., (1981):**
PUVA treatment and skin cancer: a following-up study. *Acta. Derm. Venereol (Stockh)*; 61:141.
194. **Lee, A.Y. and Jang, J.H. (1998):**
Autologous epidermal grafting with PUVA-irradiated donor skin for the treatment of vitiligo. *Int J Dermatol*; 37(7):551-4
195. **Leeuwenberg, J.F.; Smeets, E. et al., (1998):**
E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells n vitro. *Immunology*; 77:543.
196. **Le Poole, I.C. et al., (1993 a):**
Review of the etiopathomechanism of vitiligo: A convergence theory. *Exp. Dermatol*; 2:145-153.
197. **Le Poole, I.; Wijngaard, R.; Westerhof, W. et al., (1993 b) :**
Presence or absence of melanocytes in vitiligo lesions: An immunohistochemical investigation. *J. Invest. Dermatol*; 100:816.
198. **Lerman, S.; Megaw, J. et al., (1980):**
Potential ocular complications from PUVA therapy and their prevention. *J. Invest. Dermatol*; 74:197.

-
199. Lerner, A. (1959):
Vitiligo. *J. Invest. Dermatol.*, 32:285. Quoted from (Kovasc, 1998)
200. Lerner, A. (1971):
On the etiology of vitiligo & gray hair. *Am. J. Med.*, 51:141(Abstr). } Quoted
201. Lerner, A. and Nordlund, J. (1978):
Vitiligo. What is it? Is it important? *JAMA*; 239:1183.
Quoted from (Kovasc, 1998)
202. Lever, L.R. and Farr, P.M. (1994):
Skin cancers on premalignant lesions occur in half of high-dose PUVA patients. *Br.J.Dermatol*; 131:215.
203. Levy, S.B. (2001):
Cosmetics that imitates a tan. *Dermatol Ther*, 14:215
204. Li, Y.L.; Yu, C.L. and Yu, H.S. (2000):
IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and ICAM-1 expression and an increase in IL-8 release by melanocytes. *J Invest Dermatol*; 115(6): 969-73.
205. Lisa, A.R.; Lili, T. et al., (1998):
The role of adhesion molecules in human leukocyte attachment to porcine vascular endothelium. *J.Immunol*; 161:6931.
206. London, I. (1959):
Evaluation of methoxsalen in the treatment of vitiligo. *J.Invest.Dermatol*; 32:315. Quoted from (Kovasc, 1998)
207. Lub, M.; Van Kooyk, Y. et al., (1995):
Ins and outs of LFA-1. *Immunol Today*; 16:479-83.
208. Lubomira, S.; Kim, J. and Henry, W. (2001):
Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. *J Am Acad Dermatol*; 44:999-1003.
209. Lynn, A.; Scott, M. et al., (1996):
Guidelines of care for vitiligo. *J.AM.Acad.Dermatol*; 35:620 – 6.
-

-
210. **Majumder, P.; Das, S. and Li, C. (1988):**
A genetical model for vitiligo. *Am. J. Hum. Genet*; 43:119-25.
 211. **Maler, H. et al., (1996):**
Skin tumors in photochemotherapy for psoriasis: A single center follow-up of 496 patients. *Dermatology*; 193:185.
 212. **Mandry, R.C.; Ortiz, L.J. et al., (1996):**
Organ specific autoantibodies in vitiligo patients & their relatives. *Int. J. Dermatol*; 35:18.
 213. **Mancusco, G.; Berdondini, R.M. et al., (1996):**
Occupational dermatitis in shoemakers contact Dermatitis; 34:17-22.
 214. **Morelli, J.G. et al., (1992):**
Leukotriene C4 and TGF alpha are stimulators of human melanocytes migration in vivo. *J Invest Dermatol*; 98:290
 215. **Martinez, J.A.; Lopez, P.F.; Sternber, G.P. et al., (1992):**
Vogot-Koyanadgi-Harada syndrome in patients with cherokee Indian ancestry. *Am J Ophthalmol*; 114:615-20.
 216. **Mary, B.M. et al., (1999):**
Promotion of neutrophil chemotaxis through different regulation of beta 1 & beta 2 integrins. *J. Immunol*; 162: 6992.
 217. **McEvoy, M.T. and Stern, R.S. (1987):**
Psoralens and related compounds in the treatment of psoriasis. *Pharmac. Ther*; 34:75.
 218. **Melski, J.W. et al., (1997):**
Oral methoxsalen photochemotherapy for the treatment of psoriasis: A cooperative clinical trial. *J. Invest. Dermatol*; 68:328.
 219. **Merimsky, O.; Shoenfeld, Y. et al., (1996) :**
Vitiligo and melanoma – associated hypopigmentation : a similar appearance but a different mechanism. *Cancer Immunol Immunother*.38:411-6.
 220. **Miller, R.A. (1982):**
Psoralen and UVA induced stellate hyperpigmented freckling. *Arch. Dermatol.*, 1118:619.
-

221. **Miller, K.E. and Graves, J.C. (2000):**
Sensitivity of pigmented mucosa and pigmented cells in skin due to freezing injury. *Cryobiology*; 16:348
222. **Moellmann, G.; Klein-Angerer, S.; Scollay, A. et al. (1982):**
Extracellular granular material & degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. *J. Invest. Dermatol*; 79:321-30.
223. **Momtaz, K. and Fitzpatrick, T.B. (1998):**
The benefits and risks of long-term PUVA photochemotherapy. *Dermatologic Clinics*, 16(2):227.
224. **Montazeri, A.; Kanitakis, J. et al., (1995):**
Expression of ICAM-3/CD50 in normal and diseased skin. *Br.J.dermatol*; 133:377.
225. **Moorthy, R.S.; Inomata, H. and Rao, N.A. (1995):**
Vogot-Koyanadgi-Harada syndrome .*Surv Ophthalmol*, 39:265-92.
226. **Morelli, J.G. et al., (1992):**
Leukotrienr C4 & TGF alpha are stimulators of human melanocytes migration in vivo. *J invest Dermatol.*; 98:290
227. **Moretti, S.; Spallanzani, I. et al., (2002):**
New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions. *Pigment Cell. Res. Apr.*; 15(2): 87-92.
228. **Morison, W.L.; Parrish, J.A. et al.,(1980):**
In vivo effects of PUVA on lymphocyte function. *Br. J. Dermatol.*, 104:405.
229. **Morison, W.L.; Parrish, J.A. et al., (1981):**
Sensitivity of mononuclear cells to PUVA: Effect on subsequent stimulation with mitogens and on exclusion of trypan blue dye. *Clin. Exp. Dermatol.*, 6:273.
230. **Morison, WmL. et al., (1983):**
Abnormal lymphocyte function following long term PUVA therapy for psoriasis. *Br. J. Dermatol.*, 108:445.
-

231. **Morohashi, M.; Hashimoto, K. et al., (1977):**
Ultrastructural studies of vitiligo, Vogt Kayanagi syndrome and incontinentia pigmenti achromians. Arch. Dermatol. , 113: 755. Quoted from (E. Helen, Elizabeth and Anthony, 2000) 23
232. **Moscicki, R.A.; Morison, W.I. et al., (1982):**
Reduction of the function of circulating helper-inducer T-cell identified by monoclonal antibodies in psoriatic patient treated with long-term psoralen/ultraviolet. A radiation (PUVA). J. Invest. Dermatol., 79:205. E. Helen et al
233. **Mosher, D.B.; Fitzpatrick, T.B. et al., (1993):**
Disorders of pigmentation in Dermatology in general medicine. Fitzpatrick TB. Eisen AZ. Wolff K. Freedberg IM and Austen KF (eds) Fourth edition Mc Graw-Hill Inc. New York: 903.
234. **Mosher, D.B.; Fitzpatrick, T.B. et al., (1999):**
Hypomelanoses and Hypermelanoses. In: Fitzpatrick;s Dermatology in General Medicine, ch. 89. p. 949.
235. **Mysore, V. (2002):**
A comment on dressing for the recipient area of split-thickness skin graft in vitiligo. J Am Acad Dermatol; 46 (6):961
236. **Muller, W.A.; Weigl, S.A. et al., (1993):**
PECAM-1 is required for transendothelial migration of leukocytes. J.Exp.Med; 178:449.
237. **Nahla, S. Hunter. (1998):**
A study of ICAM-1 in psoriasis. J.Invest. Dermatol; 91:684.
238. **Nair, B.K. (1978):**
Vitiligo: A retrospect. Int. J. Dermatol, 17: 755 - 7. Quoted from (Kovasc, 1998)
239. **Naughton, G.; Eisinge, M. and Bystry, J. et al., (1983) :**
Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J. Invest. Dermatol. , 81: 540.

240. **Naukkarinen, A. et al., (1989):**
Quantitation of cutaneous nerves and their substance P content in psoriasis. *J. Invest. Dermatol.*, 92:126-9.
241. **Nihei, V.; Nishibu, A. et al., (1998):**
Suplatast tosilate, a new immunoregulator, is effective in vitiligo treatment. *J Dermatol*; 25 :250
242. **Njoo, M.D. and Westerhof, W. (1997):**
Vitiligo: *Ned.Tijdschr.Geneeskd.*, 141 (16) : 759 (English abst.)
243. **Njoo, M.D.; Spuls, P.I. et al., (1998):**
Non-surgical repigmentation therapies in vitiligo. *Arch Dermatol*; 134:1532.
244. **Njoo, M.D.; Bos, J.D. et al., (2000a):**
Treatment of generalized vitiligo in children with narrow band UVB radiation therapy. *J Am Acad Drmatol*; 42(2Pt 1):245
245. **Njoo, M.D.; Vodegel, R.M. et al., (2000b):**
Depigmentation therapy in vitiligo universalis with topical 4-methyloxuphenol and the Q-switched ruby laser. *J Am Acad Dermatol*; 42:760
246. **Nordlund, J.J. and Lerner, A.B. (1982):**
Vitiligo: It is important. *Arch Dermatol*, 118:5-8.] ??
247. **Nordlund, J.J. and Ortoone, J.P. (1992):**
Vitiligo and depigmentation, in *Current Problems in Dermatology*, St Louis, edited by WL Weston et al. Mosby-Year Book.
248. **Nordlund, J.J. et al., (1993):**
Management of vitiligo. *Dermatologic Clinics* , 11 : 27 .
249. **Nortamo, L.I.; Renkonen, R. et al., (2001):**
The expression of human ICAM-2 is refractory to inflammatory cytokines. *Eur J Immunol*; 21:2629
250. **Nose, A.; Tsuji, K. and Takeichi, M. (1990):**
Localization of specificity determine sites in cadherin cell adhesion molecules cell, 61:147.

251. Ogg, G.S. et al., (1998):
High frequency of skin homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. *J.Exp.Med.*, 188,1203-1208.
252. Okamoto, T. et al., (1998):
Anti-tyrosinase-related protein 2 immune response in vitiligo patients and melanoma patients receiving active specific immunotherapy. *J.Invest.Dermatol.* 111; 1034-1039.
253. Olsson, M.J. and Juhlin, L. (1995):
Transplantation of melanocytes in vitiligo. Related articles, Books, LinkOut. *Br.J.Dermatol*;Apr:132(4):587-91.(abstract).
254. Olsson, M.J. and Juhlin, L. (1996):
Vitiligo. *Br.J.Dermatol*; 135:852.
255. Olsson, M.J.; Juhlin, L. et al., (1997):
Repigmentation of vitiligo by transplantation of cultured Autologous melanocytes. *Acta Dem Venereol*; 77:49
256. Orecchia, G.; Perfetti, L. et al., (1992):
Vitiligo is associated with a significant increase in HLA-A30, CW6 & DQW3 & a decrease in C4 AQO in northern Italian patients. *Dermatology*,185(2) :123.
257. Ortel, B.; Tanew, A. et al., (1988):
Treatment of vitiligo with Khellin and UVA. *J. Am. Acad. Dermatol.*, 18 : 693.
258. Ortonne, J.P. et al., (1989):
Psoralen therapy in vitiligo. *Clin.Dermatol.*,7:120.
259. Ortonne, J.P. and Bose, S.K. (1993):
Vitiligo: Where do we stand? *Pigment Cell Res*; 6:61.
260. Ortoone, J.P.; Philippe, B. et al., (2003):
Hypomelanoses and Hypermelanoses. edited from Fitzpatrick's dermatology in general medicine 6th edition Mc Graw-Hill medical publishing division. P. 836-881.

-
261. **Osborn, L.; Hession, C. et al., (1989):**
Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. *Cell*; 59:1203.
262. **Ozdemir, M.; Cetinkale, O. et al., (2002):**
Comparison of two surgical approaches for treating vitiligo: a preliminary study. *Int J Dermatol*; 41(3):135-8
263. **Papadopoulos, L.; Bor, R. et al., (1998):**
Impact of life events on the onset of vitiligo in adults: Preliminary evidence for a psychological dimension in etiology. *Clin Exp Dermatol*; 23(6):243-8
264. **Papadopoulos, L.; Bor, R. et al., (1999):**
Coping with the disfiguring effects of vitiligo: A preliminary investigation into the effects of cognitive-behavioral therapy. *Br J Med Psychol*; 72(Pt3):385-96
265. **Pardi, R.; Inveardi, L. et al., (1992):**
Regulatory mechanisms in leukocyte adhesion: flexible receptors for sophisticated travelers. *Immunol Today*; 13:224-30.
266. **Parrish, J.A. et al., (1976):**
Photochemotherapy of vitiligo. *Arch. Dermatol*; 112:1531. Quoted from (Honigsmann et al., 1992)
267. **Parsad, D.; Saini, R. and Verma, N. (1998):**
Combination of PUVA sol and topical calcipotriol in vitiligo. *Dermatology*; 197:167
268. **Parsad, D.; Pandhi, R. et al., (2004):**
Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. *J Am Acad Dermatol*; 50:63-7.
269. **Pasricha, J.S.; Seetharam, K.A. et al., (1989):**
Evaluation of five different regimens for the treatment of vitiligo. *Indian J Dermatol Venereol Leprol*; 55:18. Quoted from (Pasricha and Khaitan, 1993)
-

270. **Pasricha, J.S. and Khera, V. (1994):**
Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading diseases. *Int J Dermatol*; 33:584
271. **Pathak, M.A. (1961):**
Mechanisms of psoralen photosensitization and in vivo biological action spectrum of 8-methoxypsoralen. *J. Invest. Dermatol*; 37:397. Quoted from (Kvasc, 1998)
272. **Pathak, M.A. and Joshi, P.C. (1984):**
Mechanisms of psoralen photosensitization and in vivo biological action spectrum of 8-methoxypsoralen. *J. Invest. Dermatol*; 37:397.
273. **Pathak, M.A. and Fitzpatrick, T.B. (1994):**
Preventive treatment of sunburn, dermatoheliosis and skin cancer with sunprotective agents. In Fitzpatrick TB.; Eisen AK.; Wolff K.et.al.(eds):*Dermatology in General Medicine*, ed 4 New York, Mc Graw-Hill, pp 1689.
274. **Perkins, W. et al., (1990):**
Cutaneous malignancy in males treated with photochemotherapy. *Lancet*; 336:1248.
275. **Picardi, A.; Pasquini, P. et al., (2003):**
Stressful life events, social support, attachment security and alexithymia in vitiligo. A case control study. *Psychother Psychosom*; 72(3):150-8.
276. **Pigott, R. and Power, C. (1993):**
The adhesion molecules. In: *Facts book*, Pigott R. and Power C.(eds), Academic Press ,San Diego,p.70.
277. **Pigott, R.; Dillon, L.P. et al., (1999):**
Soluble form of E-selectin, ICAM-1 and VCAM-1 are present n supernatants of cytokine activated culture endothelial cells. *Biochem. Biophys. Res. Commun.*; 187:584.
278. **Playfair, J.H.L. and Lydyard, P.M. (2000):**
Medical immunology made memorable. Edinburgh London New York Philadelphia St. Louis Sydney Toronto .p.58.

279. **Rajesh. S. (2004):**
Vitiligo assessment test.
<http://www.askdrashah.com/lueco.htm>.
280. **Renkonen, R.; Paavonen, T. et al., (2002):**
Expression of endothelial adhesion molecules in vivo: Increased endothelial ICAM-2 expression in lymphoid malignancies. *Am J Pathol*; 140:753
281. **Reolandts, R. (1991):**
The history of photochemotherapy. *Photodermatol .Photoimmunol . Photomed*; 8:184.
282. **Reymond, J.L. et al., (1980):**
Superficial actinic porokeratosis in a patient undergoing long term PUVA therapy. *Acta. Derm. Venereol. (Stockh)*; 60:539-40.
283. **Roenigk, H.H. and Caro, W.A. (1981):**
Skin cancer in the PUVA-48 cooperative study. *J.Am.Acad.Dematol*; 4:319.
284. **Rogers, S.; et al., (1979):**
Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. *Lancet*; 1:455-8. Quoted from (Honigsmann et al., 1992)
285. **Rosario, R.; Mark, G.I. et al., (1979):**
Histological changes produced in skin by equally erythemogenic doses of UVA,UVB,UVC and UVA with psoralens. *Br. J. Dermatol*; 1:299. Quoted from (Goldstein, 1992b)
286. **Rothlein, R.; Mainolfi, F.A. et al., (1991):**
A form of circulating ICAM-1 in human serum. *J. Immunol*; 147:3788.
287. **Ruggero, P.; Luca, I. et al., (1992):**
Regulatory mechanisms in leukocyte adhesion: Flexible receptors for sophisticated travelers. *J Immunol Today*; 13:224
288. **Ruoslahti, E. and Pierschbacher, M.D. (1986):**
Arg-Gly-Asp: a versatile cell recognition signal. *Cell.*; 44:517.

289. Sako, D. et al., (2000):
Selectin. Cell; 75:1179.
290. Sandrin, M.S.; Mouhtouris, E. et al., (1998):
,CD48 is a low affinity ligand for human CD2. J.Immunol.151:
4606.
291. Schallreuter, K.U. and Pittelkow, M.R. (1988):
Defective calcium uptake system in vitiligo. Arch. Dermatol.
Res., 280: 137.
292. Schallreuter, K.U.; Wood, J.M. and Berger, J. (1991):
Low catalase levels in the epidermis of patients with vitiligo. J.
Invest. Dermatol. 97:1081-1085.
293. Schallreuter, K.U.; Wood, J.M. et al., (1994):
Regulation of melanin biosynthesis in the human epidermis by
tetrahydrobiopterin. Science 263:1444-1446.
294. Schallreuter, K.U.; Wood, J.M. et al., (1995):
Treatment of vitiligo with a topical application of
pseudocatalase and Ca ++ in combination with short term UVB
exposure: A case study on 33 patients. Dermatology, 190:223.
295. Schallreuter, K.U.; Wood, J.M. et al., (1996):
Increased monoamine oxidase. An activity in the epidermis of
patients with vitiligo. Arch. Dermatol. Res., 288: 14.
296. Schallreuter, K.U and Wood, J.M. (1996):
Catecholeamines in vitiligo. Dermatology, 192: 191.
297. Schaumburg, I.L. (2001):
Study confirms effectiveness of Revolutionary vitiligo
treatment. AAD public resources. July.12
298. Scherschun, L.; Kim, J.J. and Lim, H.W. (2001):
Narrow-band ultraviolet B is auseful and well-tolerated
treatment for vitiligo. J Am Acad Dermatol; 44(6):999
299. Schleiffenbaum, B. et al., (2002):
L-selectin. J.Cell.Biol 119:229.

300. Schopf, R.E.; Naumann, S. et al., (1993):
Soluble ICAM-1 levels in-patients with psoriasis.
Br.J.Dermatol.128: 34
301. Schukla, S.R. (1983):
Evaluation of clofazimine in vitiligo. Dermatologicas;
163:169. Quoted from (Goldstein et al., 1992b)
302. Selvaag, E. (1996):
Chloroquine-induced vitiligo. Acta Derm Venereol (Stockh), 76;
166-7.
303. Seth, R.; Raymond, F.D and Makgaba, M.W. (1991):
Circulating ICAM-1 isoforms: diagnostic prospects for
inflammatory and immune disorders. Lancet, 338:83.
304. Sharque, K.E. (1984):
Vitiligo: Clin Exp Dermatol, 9: 117 – 26.
305. Shattli, S.J. et al., (1994):
Adhesion signaling in platelets. Curr. Opin. Cell. Biol.; 6:695-
704.
306. Shenoi, S.D.; Srinivas, C.R. and Pai, S. (1997):
Treatment of stable vitiligo with autologous epidermal grafting.
J.Am.Acad.Dermatol; 37:802-803.
307. Spencer, J.; Nossa, R. and Ajmer,i J. (2002):
Treatment of vitiligo with the 308-nm excimer laser: A pilot
study. J Am Acad Dermatol; 46:727-31.
308. Springer, T.A.; Dustin, M.L. et al., (1997):
The lymphocyte function associated LFA-1, CD2 and LFA-3
molecules: cell adhesion receptors of the immune system. Annu
Rev,Immunol; 5: 233.
309. Springer, T.A. (2003):
Traffic signals for lymphocyte recirculation and leukocyte
emigration: the multistep paradigm. Cell; 76:301.

310. **Smith, C.W. (1996a):**
Cellular adhesion and interaction. In: Clinical immunology Principles and Practice, Rich, RR. Fleisher, TA.; Schwartz DD.; Shear WT. And Strober W. (eds), Mosby-Year book, Inc., St.Louis, London, Madrid, Mexico city, Singapore, Sydney, Tokyo and Toronto, p.176-191.
311. **Smith, C.W.; Marlin, S.D. et al., (1989):**
Co-operative interactions of LFA-1 & Mac-1 with intercellular adhesion molecule in facilitating transendothelial migration of human neutrophils in vitro. J.Clin.Invest; 83: 2008.
312. **Smith, P.D. (1996 b):**
The microcirculation in venous hypertension. Cardio.Vasc. Rs; 32(4): 789.
313. **Stern, R.S.; Parrish, J.A. et al., (1985):**
Ocular findings in patients treated with PUVA. J. Invest. Dermatol; 85:269.
314. **Stern, R.S. et al., (1988):**
Non-melanoma skin cancer occurring in-patients treated with PUVA five to ten years after first treatment. J. Invest. Dermatol; 91:120.
315. **Stern, R.S. et al., (1990):**
Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. N. Engl. J.Med; 322:1093.
316. **Stern, R.S. and Vakeva, L.H. (1997):**
Non-cutaneous malignant tumors in the PUVA follow-up study. J. Invest. Dermatol; 108:897.
317. **Stites, D.P. (1994):**
Clinical laboratory methods for detection of cellular immunity in Basic & clinical immunology (8th eds) (Stites DP., Terr AI. and Parslow TG. eds) pp199. Appleton & Lange. Norwalk, CT, USA.
318. **Strauss, G.H.; Bridges, B.A. et al., (1980):**
Inhibition of delayed hypersensitivity reaction in skin (DNCRB test) by 8-methoxypsoralen photochemotherapy. Lancet; 13:556.

319. **Suga, Y.; Butt, K.I. et al., (1996):**
Successful treatment of vitiligo with PUVA – pigmented autologous epidermal grafting. *Int. J. Dermatol*; 35:518-522.
320. **Suvanprakorn, P.; Dee-Ananlap, S. et al., (1999):**
Melanocyte Autologous grafting for treatment of leukodermas. *J Am Acad Dermatol*; 13:968-74.
321. **Taieb, A. (2000):**
Intrinsic and extrinsic pathomechanisms in vitiligo. *Pigment Cell Res.*; 13:41-47.
322. **Tanaka, Y.; Albelda, S.M.; Horgan, K.J.; Van Seventer, G.A.; Shimizu, Y.; Newman, W. (1999):**
CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion. *J. Exp. Med.*; 176:245
323. **Taneija, A. (2002):**
Treatment of vitiligo. *J Dermatolog*; 13(9):19
324. **Tanew, A.; Honigsmann, H. et al., (1988):**
5 methoxypsoralen (Bergapten) for photochemotherapy: bioavailability, phototoxicity and clinical efficacy in psoriasis of a new drug preparation. *J. Am. Acad. Dermatol.*; 18:333.
325. **Tanew, A. and Ferguson, J. (2001):**
Phototherapy and photochemotherapy of the idiopathic photodermatoses, In *Dermatology Phototherapy and Photodiagnostic Methods*, edited by J Krutmann, et al., Berlin, Springer, p 122.
326. **Tang, A.; Amagi, M. and Granger, L.G. (1998):**
Adhesion of epidermal Langerhans cell to keratinocytes mediated by E-cadherin *Nature*, 361:82.
327. **Tang, W.Y.; Chan, L.Y. et al., (1998):**
Treatment of vitiligo with Autologous epidermal transplantation using the roofs of suction blisters. *Hong Kong Med J.*; 4(2):219

328. **Tedder, T.F.; Steeber, D.A. et al., (1995):**
The selectins: Vascular adhesion molecules. *FASEB J.*; 9:866-73.
329. **Tedder, T.F. (1999):**
Adhesion molecules I. *J.Exp.Med* 170-183.
330. **Thomsen, K. and Schmidt, H. (1976):**
PUVA induced bullous pemphigoid. *Br. J. Dermatol.*; 95:568.
Quoted from (Irwin, Arthur, et al., 2003)
331. **Thissen, M. and Westerhof, W. (1997):**
Laser treatment for further depigmentation in vitiligo. *Int J Dermatol*; 36:386
332. **Tobin, D.J.; Swanson, N.N. et al., (2000):**
Melanocytes are not absent in lesional skin of long duration vitiligo. *J Pathol*; 191(4):407-16
333. **Toda, K.; Danno, K. et al., (1986):**
Effect of 8-methoxypsoralen plus long wave ultraviolet (PUVA) radiation on mast cells.II. In vitro PUVA inhibits degranulation of rat peritoneal mast cells induced by compound 48/80.*J.Invest.Dermatol.*; 87:113.
334. **Tohma, S.; Hirohata, S. et al., (1991):**
The role of CD11a/CD18-CD54 interaction in human T-cell dependent B-cell activation. *J Immunol*; 146:492
335. **Tomita, Y.; Torinuk, W. and Tagami, H. (1988):**
Stimulation of human leukocytes by vitamin D³ possibly mediates skin pigmentation after sun exposure. *J Invest Dermatol*; 83:884
336. **Tosti, A.; Bardazzi, F.; De Padova, M. et al., (1986):**
Deafness & vitiligo in an Italian family. *Dermatologica.*; 172:178-9.
337. **Treina, G.; Scaletta, C. et al., (1996):**
Expression of intercellular adhesion molecule-1 in UVA irradiated human skin cells in vitro and in vivo. *Br J Dermatol*; 135:241.
-

338. **Tsu-Yi, C.; Lori, A.H. et al., (1992):**
PUVA and skin cancer. A historical cohort study on 492 patients. *J. Am. Acad. Dermatol.*; 26:173.
339. **Tsuji, T. and Cox, A.J. (1978):**
Ultra structural changes in nuclei and nucleoli in psoriatic epidermis during and after PUVA therapy. *Acta. Derm. Venereol. (Stockh)*; 58:383. Quoted from (Kovasc, 1998)
340. **Tsuji, T.; Nagata, K. et al., (1994):**
Induction of superoxide anion production from monocytes and neutrophils by activated platelets through the p selectin sialyl Lewis-X-interaction. *J.Leukoc.Biol.*; 56:583-7.
341. **Urbanek, R.W. (1983):**
Tar vitiligo therapy. *J An Acad Dermatol*; 8:755
342. **Vallant, V.P.; Gilleaudeau, P. et al., (1994):**
PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis : A possible cellular basis for remissive therapy. *J.Exp.Med.*; 180(1):283(abstract).
343. **Van Kooyk, Y. et al., (1994):**
Extracellular Calcium modulates leukocyte function associated antigen -1 cell surface distribution on T lymphocytes and consequently affects cell adhesion. *J. Cell. Biol.*; 124:1061-70.
344. **Van De Stolpe, A. and Van De Saag, P.T. (1996):**
Intercellular adhesion molecule-1. *J. Mol. Med. Jan.*; 74(1):13-33.
345. **Van Den Wijngaard, R. et al. (2000):**
Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA T cells at the perilesional site. *Lab.Invest.*; 80:1299-1309.
346. **Van Praag, M.C.G.; et al., (1993):**
PUVA keratoses: A clinical and histopathologic entity associated with an increased risk of non-melanoma skin cancer. *J. Am. Acad. Dermatol.*; 28:412-7.

347. **Van Scott, E.J. and Yu, R.J. (1975):**
Melanogenesis from topical mechlorethamine and analogues in skin of hairless mice and in vitiligo. *J Invest Dermatol*; 64:476. Quoted from (Goldstein, 1992b)
348. **Van Weelden, H.; De la Faille, H.B. et al., (1998):**
New development in UVB phototherapy of psoriasis. *Br J Dermatol*; 119:11
349. **Wakita, H.; Sakamoto, T. et al., (1994):**
E-selectin and vascular cell adhesion molecule-1 as critical adhesion molecules for infiltration of T lymphocytes and eosinophil in atopic dermatitis. *J.Cutan.Pathol.*; 21:33-9.
350. **Walter, J.F. et al., (1973):**
Psoralen plus black light inhibits epidermal DNA synthesis. *Arch. Dermatol.*; 107:861. Quoted from (Honigsmann et al., 1992)
351. **Weller, A. et al., (1999):**
Selectin. *J. Biol. Chem* 267:15176.
352. **Westerhof, W. and Nieuweboer-Krobtova, L. (1997):**
Treatment of vitiligo with UVB radiation vs. topical psoralen plus UVA. *Arch Dermatol*; 133:1525
353. **Westerhof, W.; Lontz, W.; Vanscheid W.; Braathen, L. (2001)**
Vitiligo: News in surgical treatment. *J. Eur. Acad. Dermatol. Venereol*; 15 (6):511
354. **Williams, A.F. and Barclay, A.N. (1999):**
Superfamily: domains for cell surface recognition. *Ann. Rev. Immunol.*, 6:381.
355. **William, Y.M.T.; Jian, D.H.; Nian, Z.L.; Loi Y.C.; Kuen, K.L. (1999):**
Surgical Pearl: Fine gauze is a useful carrier for epidermal graft in the treatment of vitiligo by means of the suction blister method. *J. Am. Acad. Dermatol*; 40:247-9
356. **Wolff, K.; Fitzpatrick, T.B. et al., (1976):**
Photochemotherapy with orally administered methoxsalen. *Arch. Dermatol.*; 112:943. Quoted from (Goldstein, 1992b)

357. **Wolff, K.; Gschnait, F. et al., (1977):**
Phototesting and dosimetry for photochemotherapy. *Br. J. Dermatol.*; 96:1. Quoted from (Goldstein, 1992b)
358. **Wolff, K. and Honigsmann, H. (1981):**
Clinical aspects of photochemotherapy. *Pharmacol. Ther.*; 12:381.
359. **Wolff, K. (1990):**
Side effects of psoralen photochemotherapy (PUVA). *Br. J. Dermatol.*; 122 (Suppl) 36:117-125.
360. **Wolff, K. and Honigsmann, H. (1991):**
Genital carcinomas in psoriasis patients treated with photochemotherapy. *Lancet.*; 337:439.
361. **Wolverton, S.E. and Wilkin, J.K. (1991):**
Psoralen In: *Systemic drugs for skin diseases* (eds), 1st edit, WB. Saunders Company, Philadelphia, London, 219-246.
362. **Woolfson, H. and Finn, O.A. (1972):**
Topical levodopa in vitiligo. *Lancet*; 1:598. Quoted from (Goldstein et al., 1992b)
363. **Wulf, H.C. and Andreassen, M.P. (1981):**
Distribution of H-8-MOP and its metabolism in rat organs after a single oral administration. *J. Invest. Dermatol.*; 76:252.
364. **Yalcin, B.; Sahin, S. et al., (2001):**
Experience with calcipotriol as adjuvant treatment for vitiligo in patients who do not respond to PUVA alone. A preliminary study. *J Am Acad Dermatol*; 44:634
365. **Yamamoto, T. et al. , (1995):**
Verruciform xanthoma in psoriatic patient under PUVA therapy. *Dermatology.*; 191:254-256.
366. **Youn, J.I.; Park, B.S. et al., (1997):**
Photoprotective effect of calcipotriol upon skin photoreaction to UVA and UVB. *Photodermatol Photoimmunol Photomed*; 13:109

367. **Young, A.R. and Magnus, L.A. (1981):**
An action spectrum for 8-MOP induced sunburn cells in mammalian epidermis. *Br. J. Dermatol.*; 104:451.
368. **Young, A.R.; Magnus, I.A. et al., (1983):**
A comparison of the phototumorigenic potential of 8-MOP and 5-MOP in hairless albino mice exposed to solar stimulated radiation. *Br. J. Dermatol.*; 108:507.
369. **Yu, H.S.; Chang, K.L. et al. (1997):**
Alterations in IL-6, IL-8, GM-CSF, TNF- α , and IFN- γ release by peripheral mononuclear cells in-patients with active vitiligo. *J. Invest. Dermatol.*; 108:527-529.
370. **Yu, H.S.; Wu, C.S. et al., (2003):**
Helium-neon laser irradiation stimulates migration and proliferation in melanocytes and induces repigmentation in segmental-type vitiligo. *J Invest Dermatol*; 120:56
371. **Zala, L.; Omar, A. et al., (1977):**
Photo-onycholysis induced by 8-methoxypsoralen. *Dermatologica.*; 154:203. Quoted from (Goldstein, 1992b)
372. **Zambruno, G.; Cossarizza, A. et al., (1995):**
Functional intercellular adhesion molecule-3 is expressed by freshly isolated epidermal Langerhans cells and is not regulated during culture. *J Invest Dermatol*; 105:215
373. **Zarebska, Z. (1994):**
Cell membrane, a target for PUVA therapy. *J.Photochem. Photobiol. B.*; 23:101 (abstract).
374. **Zelickson, A.S.; Mottaz, J.H. et al., (1980):**
Elastic tissue changes in skin following PUVA therapy. *J.Am.Acad.Dermatol.*; 3:186.
375. **Zheng, R.Q. et al., (1990):**
Expressing of ICAM-1 & lymphocyte associated antigen-3 on human thyroid epithelial cells in Graves & Hashimoto's disease. *J. Autoimmune.* 3; 727-736